Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of cross-sectional differences and longitudinal changes to the morphometry of the brain following paediatric traumatic brain injury.

NeuroImage. Clinical·2019
Same author

Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Genomics and outbreaks: foot and mouth disease.

Revue scientifique et technique (International Office of Epizootics)·2016
Same author

Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Journal of thrombosis and haemostasis : JTH·2014
Same author

FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2013

Related Experiment Video

Updated: Jul 15, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Heparin-associated thrombocytopenia.

D J King, J G Kelton

    Annals of Internal Medicine
    |April 1, 1984
    PubMed
    Summary

    Heparin-associated thrombocytopenia, a complication of heparin therapy, can lead to serious arterial thrombosis. Early oral anticoagulant use alongside heparin may prevent most of these adverse events.

    Area of Science:

    • Pharmacology and Toxicology
    • Hematology

    Background:

    • Heparin therapy can lead to heparin-associated thrombocytopenia (HAT) in about 5% of patients.
    • HAT incidence is higher with bovine heparin compared to porcine heparin.
    • HAT typically manifests 6-12 days post-heparin initiation, with low morbidity on its own.

    Purpose of the Study:

    • To investigate the complications and potential prevention strategies for heparin-associated thrombocytopenia.
    • To explore the link between HAT and arterial thrombosis.
    • To evaluate the efficacy of early oral anticoagulant administration in preventing HAT.

    Main Methods:

    • Review of clinical data on heparin-associated thrombocytopenia incidence and outcomes.
    • Analysis of the typical onset time of HAT.

    More Related Videos

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
    04:32

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

    Published on: June 5, 2019

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

    Related Experiment Videos

    Last Updated: Jul 15, 2026

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
    11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
    04:32

    A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

    Published on: June 5, 2019

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
    04:37

    Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

    Published on: May 23, 2025

  • Consideration of diagnostic methods, including heparin-dependent platelet-aggregating factor testing.

    • Main Results:

    • Heparin-associated thrombocytopenia plus arterial thrombosis can result in severe complications like stroke, heart attack, and death.
    • The co-occurrence of HAT and arterial thrombosis is less frequent than HAT alone.
    • Diagnosis of HAT is often by exclusion, but specific factor testing may aid diagnosis.

    Conclusions:

    • A strategy involving concomitant initiation of oral anticoagulants with heparin, followed by early heparin discontinuation, may prevent most HAT episodes.
    • Understanding the temporal profile of HAT onset is crucial for developing preventive measures.
    • Further research into diagnostic markers and preventive interventions is warranted.